Upperton Pharma Solutions Wins Champion Award at 2025 CDMO Leadership Awards

• Upperton Pharma Solutions won the Champion Award in the Small Molecule Dosage Form – International category at the 2025 CDMO Leadership Awards.

• The recognition is based on direct feedback from pharmaceutical and biotech companies working with CDMOs.

Upperton Pharma Solutions has been named a Champion Winner in the Small Molecule Dosage Form – International category at the 2025 CDMO Leadership Awards. The awards, presented by Outsourced Pharma and Life Science Connect, recognise contract development and manufacturing organisations (CDMOs) that demonstrate outstanding performance, as determined by direct feedback from pharmaceutical and biotech companies.

The award ceremony took place on 19 March 2025 at THE POOL in New York City, bringing together industry leaders to celebrate excellence in pharmaceutical outsourcing and development. Upperton Pharma Solutions, a UK-based CDMO, specialises in formulation development, clinical trial manufacturing, and commercial production across multiple dosage forms, including oral solids, liquids, semi-solids, and inhalation products. The company operates a 50,000 sq ft facility in Nottingham and recently expanded with a new 7,000 sq ft sterile manufacturing facility.

Nikki Whitfield, Chief Executive Officer of Upperton Pharma Solutions, commented: “Being recognised as a Champion Award Winner in the 2025 CDMO Leadership Awards is a testament to the hard work and dedication of our entire team and highlights not only our continued business growth but also reflects the importance we place on the relationships we build and nurture with our customers.”

The award underscores the company’s industry reputation and the trust placed in its services by clients in the pharmaceutical and biotech sectors. By offering integrated CDMO services from pre-clinical development to market supply, Upperton Pharma Solutions continues to strengthen its role in the global pharmaceutical manufacturing landscape.